,404	_
L	404

NOTICE TO'	COMPLY WI	The EQUI	REMENT	s FOR	PATENT	AP CATIONS	CONTAINING
NUCLEOTIDE	SEQUENCE	AND/OR	AMINO 2	ACID	SEQUENCE	DISCLOSURES	•

UCLE	TIDE BEQUENCE AND/OR AMINO ACID BEQUENCE DISCUSSIVES	•
ot co	cleotide and/or amino acid sequence discrosure contained in this appl mply with the requirements for such a disclosure as set forth in 37 C for the following reason(s):	ication does FR 1.821 -
X	1. This application clearly fails to compay with the requirements of	5 37 CFR 1.821-
	1.825. Applicant's attention is difficulted to these regulations, publ 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	ished at 114 OG
	2. This application does not contain, as a separate part of the disc	closure on
	paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	
	3. A copy of the "Sequence Listing" in computer readable form has no	ot been
	submitted as required by 37 CFR 1.821(e).	
	4. A copy of the "Sequence Listing" in computer readable form has b	een submitted.
	However, the content of the computer readable form does not comply verified requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attackmarked-up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this applica	tion has been
	found to be damaged and/or unreadable as indicated on the attached of Problem Report. A substitute computer readable form must be submitted by 37 CFR 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the	computer
	readable form of the "Sequence Listing" as required by 37 CFR 1.821	(e).
$\boxtimes$	7. Other: See attached pages	RECEIVED
Appli	icant must provide:	FEB 1 9 2003
$\boxtimes$		CH CENTER 1600/2900
	Listing"	:
X	An initial or substitute paper copy of the "Sequence Listing", as we	ell as an
	amendment directing its entry into the specification	•
$\boxtimes$	A statement that the content of the paper and computer readable copi	es are the same
	and, where applicable, include no new matter, as required by 37 CFR 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	1.821(e) or

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Pleas return a copy of this notice with your response.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Splicant: Lorin R. DeBonte, et al.

Art Unit : 1638

Serial No.: 09/771,904

Examiner: Elizabeth F. McElwain

Filed

: January 29, 2001

Title

: FATTY ACID DESATURASES AND MUTANT SEQUENCES THEREOF

U.S. Patent and Trademark Office Mail Stop - Box Sequence PO Box 2327 Arlington, VA 22202

## VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Judith A. Wasilkus, declare that I personally prepared the paper and the computerreadable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Lebrucy 7, 2000

Fish & Richardson P.C., P.A. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 (612) 335-5070 telephone (612) 288-9696 facsimile

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

9. Wasikus

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202.

February 7, 2003

Date of Deposit

Signature

Kathryn J. Sanderson

Typed or Printed Name of Person Signing Certificate